Company / Shareholders' Equity
Dyne Therapeutics, Inc. Shareholders' Equity History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$629.8M
FY2024
5-year range
$91.3M / $629.8M
FY2020-FY2024
Trend
+589.9%
vs FY2023
Sector context
#79 of 215
Health Care
What the data says
Shareholders' Equity changed +590% YoY in FY2024, a notable deviation from the 5-year average annual change of +568%.
Based on SEC 10-K filings.
$630M in FY2024 with a 5-year CAGR of +114.0%.
Improved from $252M to $630M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +19.6%
- 5-Year CAGR
- +114.0%
- 10-Year CAGR
- -
Sector benchmark
#79 of 215 in Health CareTop 37% of 215This company $629.8M Sector average $2.6B
▼
-75.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +114.0%, indicating consistent growth.
- In FY2024, shareholders' equity increased 589.9% year-over-year.
- Ranks #79 out of 215 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $629.8M | +589.9% |
| FY2023 | $91.3M | -63.8% |
| FY2022 | $252.4M | -31.5% |
| FY2021 | $368.2M | +7.5% |
| FY2020 | $342.4M | +2339.2% |
| FY2019 | $14.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026